Evidence map›Paper›PMID 29274332›Full record

ArticleEuropean journal of pharmacology2018

Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control.

Asmaa I Matouk, Ashraf Taye, Mohamed A El-Moselhy, Gehan H Heeba, Abdel A Abdel-Rahman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Cannabinoids in the Modulation of Oxidative Signaling.International journal of molecular sciences · 2023
    Review
  4. GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries.International journal of molecular sciences · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Asmaa I MatoukDepartment of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, NC, USA.
Ashraf TayeDepartment of Pharmacology, Faculty of Pharmacy, Minia University, Egypt.
Mohamed A El-MoselhyDepartment of Pharmacology, Faculty of Pharmacy, Minia University, Egypt.
Gehan H HeebaDepartment of Pharmacology, Faculty of Pharmacy, Minia University, Egypt.
Abdel A Abdel-RahmanDepartment of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, NC, USA. Electronic address: abdelrahmana@ecu.edu.
Minia University · EGEast Carolina University · US

Funding

Sex/estrogen-dependent vulnerability to alcohol-evoked cardiotoxicity: Role of circadian rhythm regulated enzymesR01AA014441 · NIAAA · EAST CAROLINA UNIVERSITY · PI ABDEL-RAHMAN, ABDEL A · 2004 to 2022
$5.2M
NIAAA NIH HHS R01 AA014441
6 · The paper itself

Abstract

Chronic GPR18 activation by its agonist abnormal cannabidiol (trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol; abn-cbd) improves myocardial redox status and function in healthy rats. Here, we investigated the ability of abn-cbd to alleviate diabetes-evoked cardiovascular pathology and the contribution of GPR18 to this effect. Four weeks after diabetes induction by streptozotocin (STZ, 55mg/kg; i.p), male Wistar rats received abn-cbd, the GPR18 antagonist (1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-,cyclohexen-1-yl]benzene;O-1918), their combination (100µg/kg/day, i.p, each) or their vehicle for 2 weeks. Abn-cbd had no effect on diabetes-evoked cardiac hypertrophy or impaired glycemic control (hyperglycemia and hypoinsulinemia), but alleviated the associated reductions in left ventricular (LV) contractility (dP/dt

Indexed as

AdiponectinAnimalsBlood GlucoseCardiotonic AgentsDiabetes Mellitus, ExperimentalGene Expression RegulationHemodynamicsMaleMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MyocardiumNitric OxideNitric Oxide Synthase Type IIIOxidative StressPhosphorylationProto-Oncogene Proteins c-akt4-(3-3,4-p-menthadien-(1,8)-yl)olivetolAdiponectinBlood GlucoseCardiotonic AgentsGPR18 protein, ratMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nitric OxideNitric Oxide Synthase Type IIIProto-Oncogene Proteins c-aktReceptors, CannabinoidResorcinolsAbnormal cannabidiolAdiponectinCardiac dysfunctionDiabetesGPR-18O-1918

Identifiers

PMID29274332
PMCPMC5767137
OpenAlexW2780620996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.